Entrada Stock: Weak Dystrophin Data May Be Creating A Buying Opportunity
· seekingalpha.com
Entrada Therapeutics (ENTR) Buy call: $8.50 fair value (~52% upside). Valuation is anchored by risk-adjusted pipeline estimates. See more details here.
Eljaye W. Tellis is a medicinal chemistry Ph.D. candidate and biotech investor. He covers biotechnology and healthcare equities, applying a therapeutic discover...